Przegląd Gastroenterologiczny

Abstract

1/2026 vol. 21
Original paper

Irritable bowel syndrome clinical trials: getting the IBS Severity Scoring System responder rate right

  1. Department of Medicine and Health Sciences, Calisia University, Kalisz, Poland
  2. Department of Hygiene and Epidemiology, Collegium Medicum, University of Zielona Góra, Poland
Gastroenterology Rev 2026; 21 (1): 49–54
Online publish date: 2025/12/02
View full text
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease

Introduction

The Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) is frequently used to characterize treatment effects in IBS patients. Calculation of a responder rate using IBS-SSS data commonly uses a cut-off value of –50 points.

Aim

To analyze data from a recently published IBS trial to evaluate whether this cut-off value is appropriate or needs to be revised.

Material and methods

Data from 201 patients were used to establish a receiver operating characteristic (ROC) curve for IBS-SSS change data using IBS-Adequate Relief scale data as a binary classifier. The area under the curve (AUC) and its 95% CI for the ROC were determined. Curves plotting accuracy rates and Youden’s J index values against changes on the IBS-SSS used as cut-off values were employed to determine an optimal cut-off value

Results

The AUC of the ROC curve was 0.9738 (95% CI from 0.9565 to 0.9912). The curve of accuracy rates had two maxima (–122 and –133 points), while that of the Youden’s J index values had only one maximum at –122 points, considered to be the optimal cut-off value.

Conclusions

The frequently used –50 points cut-off value might not be optimal for determining clinically meaningful responder rates from IBS-SSS measurements. At least for the IBS-SSS data analyzed in the present study, a change of –122 points appears to be more appropriate. Interpretation of IBS-SSS responder rates from past or future clinical trials should carefully check for the cut-off values applied for their calculation.

Share
without publication fees